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Contagious agalactia (Ca) of small ruminants caused by Myco-
plasma agalactiae is a serious disease affecting mainly sheep and
goats characterized by mastitis, polyarthritis, keratoconjunctivitis,
and abortion (Cottew, 1979; Da Massa, 1983; Bergonier et al.,
1997). The disease occurs in Europe, Western Asia, the United
States of America (USA), North Africa, and is endemic in the Med-
iterranean Countries (Bergonier et al., 1997). Ca causes severe eco-
nomic losses in areas where economy is largely based on sheep
farming, resulting from reduced milk production and increased
lamb mortality (Lambert, 1987). Antibiotics inhibiting bacterial
cell wall assembly, such us penicillins, are not effective against
M. agalactiae, whereas tetracyclines and macrolides can sometimes
bring about clinical improvements, but they result in the selection
of unaffected carriers hosting antibiotic-resistant strains. There-
fore, M. agalactiae infection is tentatively controlled through the
implementation of hygienic measures, and through laboratory
monitoring of ﬂocks/herds with replacement of infected animals
(Nicholas, 2005). However, in addition to improved hygienic and
animal management procedures, the effective prevention of conta-
gious agalactia requires vaccination.
Both attenuated and inactivated vaccines against M. agalactiae
have been used with mixed success (Gil et al., 1999; Nicholas,
2005). Despite their intrinsic disadvantages, related to safety, difﬁ-ll rights reserved.
+39 079 229451.culty of development and production, cost, transport and storage
(Gurunathan et al., 2000), live attenuated vaccines have been used
in Turkey for many years, and have been reported to provide better
protection than inactivated vaccines. However they can produce a
transient infection with shedding of mycoplasmas (Nicholas,
2002). In Europe, where the use of live vaccines is not allowed,
attention has focused on the use of inactivated organisms. Those
which have provided protection from clinical disease have done
so to different extents (Tola et al., 1999; Greco et al., 2002). How-
ever they induce mostly a short-lived humoral immune response.
Moreover, traditional vaccines can require multiple booster shots
(inactivated vaccines), or hamper differentiation (inactivated and
attenuated) of vaccinated from infected animals (DIVA). Nucleic
acid immunization is a new promising approach to develop
effective and safe marker vaccines suitable for DIVA diagnostics
(Gurunathan et al., 2000; van Oirschot, 2001; Brandsma, 2006;
Laddy and Weiner, 2006). It has been shown that several DNA vac-
cines against mycoplasmas have the capacity to induce immune
responses in the murine model (Barry et al., 1995; Lai et al.,
1997; Chen et al., 2003; March et al., 2006). Therefore, we specu-
lated that a DNA vaccine could be also developed to controlM. aga-
lactiae infection.
Mycoplasma agalactiae, and mycoplasmas in general, trick the
immune system either by phase and size variation of their surface
antigens (Citti et al., 2000; Glew et al., 2000) or by modulating the
host immune responses through the expression of up- and down-
regulating cytokines inducing suppression or aspeciﬁc polyclonal
stimulation of B and T lymphocytes (Razin et al., 1998). Membrane
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plasmas especially by acting as cytoadhesins in the attachment of
mycoplasmas to host cells (Zhang et al., 1995; Santona et al., 2002).
Evasion of immune responses through surface antigen variability
and modulation of immunity may render vaccination ineffective.
We recently described the P48 of M. agalactiae as an invariable,
constantly expressed, immunodominant, surface lipoprotein
(Rosati et al., 1999) homologue to the MALP-404 lipoprotein of
Mycoplasma fermentans (Davis and Wise, 2002). We also developed
a commercial recombinant indirect ELISA for contagious agalactia
(Institute Pourquier, France) based on the use of the P48 antigen
lacking the leader peptide, which has been proven to be associated
to high levels of speciﬁcity and sensitivity (Rosati et al., 2000).
Therefore, P48 was the selected gene to incorporate into a DNA
vaccine againstM. agalactiae, and its potential was evaluated in the
present study by detecting and analyzing P48-speciﬁc antibodies,
the proliferation of splenocytes, and the T cell-speciﬁc cytokines
released in immunized BALB/c mice.
2. Materials and methods
2.1. Construction of expression plasmids
The mammalian expression vectors pcDNA3.1 (Invitrogen),
pVAX1 (Invitrogen), pCMV-Script (Stratagene), and the bacterial
expression vector pGEX-2T/P48 (Rosati et al., 2000), were chosen
to clone and express the P48 antigen gene of M. agalactiae. Brieﬂy,
the 1.3 kb DNA fragment containing the P48 gene, lacking the
leader peptide, was obtained by PCR (Mastercycler Gradient,
Eppendorf) from plasmid pGEX-2T/P48, using the primer pair
MagP48/BamHI/K/ATG/F (50-CTGGGATCCACGATGGTAAAAACTA
TTTCAACACTTGCA-30) and MagP48/ECO/R (50-CACGAA
TTCTTATTTTCTTGTTTCAGAAGCCAA-30). The reaction was carried
out in a thermal cycler (Mastercycler gradient, Eppendorf) with
the following proﬁles: initial denaturation at 94 C for 2 min, 35
cycles of 94 C for 300 0, 65 C for 200 0, and 72 C for 1.5 min, and a
ﬁnal extension step at 68 C for 10 min. The DNA fragment was di-
gested with BamHI and EcoRI, puriﬁed, and then inserted into
pcDNA3.1, pVAX1, and pCMV-Script, predigested with BamHI and
EcoRI, obtaining plasmids pcDNA3.1/P48, pVAX1/P48, and pCMV-
Script/P48, as DNA vaccine candidates. pGEX-2T/P48 was used to
express antigen for immunoblotting and ELISA.2.2. Expression of P48 gene in transfected cells
The human embryonic kidney cell line HEK 293 was transfected
with pcDNA3.1 or pcDNA3.1/P48, pVAX1 or pVAX1/P48, and
pCMV-Scrip or pCMV-Script/P48, alternatively, using the CalPhos
Mammalian Transfection Kit (Clontech), according to the manufac-
turer’s instructions. Transfected cells were harvested 48 h later and
washed with phosphate-buffered saline three times. Total RNA was
extracted with Trizol reagent (Invitrogen). Complementary DNA
(cDNA) was obtained from RNA with the SuperScriptTM First-Strand
Synthesis System (Invitrogen). P48 cDNA was ampliﬁed by PCR
using primers MagP48/BamHI/K/ATG/F and MagP48/ECO/R as de-
scribed above. The ampliﬁed products were analyzed with a 1%
agarose gel. Robustness of plasmids expressing P48 was evaluated
by replicating the expression experiments three times and by
immunoblotting.2.3. Immunization of mice
Twelve six-week-old female BALB/c mice (Charles River Labora-
tories) were used according to the EU International Guidelines.
Animals were isolated in individual cages and were injected intra-muscularly (T1) both in the left and the right hind thigh muscle
with either 50 lg (1 lg/ll) of pVAX1/P48 (vaccine group, six mice),
or with 50 lg (1 lg/ll) of pVAX1 (control group, six mice), alterna-
tively. Plasmid preparations were formulated in 50 ll of sterile PBS
containing 0.5% bupivacaine-HCl. Each animal was boosted with
the same dose 15 (T2) and 30 (T3) days after the ﬁrst immunization.
Serum samples, collected by tail bleeding before the ﬁrst immuni-
zation (T0), and every 14 days for 8 weeks (T1, T2, T3, Tf), were ana-
lyzed for P48-speciﬁc antibodies by Western blotting (pooled sera)
and by rP48 ELISA (each serum individually tested).
2.4. Expression and puriﬁcation of P48 antigen
Escherichia coli strain JM105 was transformed with plasmid
pGEX-2T/P48, and recombinant P48 was expressed and puriﬁed,
as previously described (Rosati et al., 2000). Brieﬂy, early log phase
cultures of positive clones, induced for 2 h with 0.5 mM isopropyl
b-thiogalactopyranoside (IPTG) were centrifuged and lysed by con-
ventional physico-chemical methods. Recombinant fusion protein
was recovered in the soluble fraction and puriﬁed by afﬁnity chro-
matography. Thrombin cleavage was performed, and purity and
yield of rP48 estimated by SDS–PAGE and Bradford method.
2.5. SDS–PAGE and western blot analysis
The puriﬁed rP48 protein was used in immunoblotting for test-
ing the presence of speciﬁc antibodies in sera of vaccinated and
control mice. Recombinant P48 and BenchMarkTM Pre-stained
Ladder (Invitrogen, Italia) were run on NuPage Novex 4–12% Bis–
Tris Zoom Gels (Invitrogen) in the XCell SureLock Mini-Cell (Invit-
rogen) according to vendor instructions. Electrophoretic transfer
onto nitrocellulose membranes (Hybond-ECL; Amersham Pharma-
cia Biotech) was done with a mini-Trans-Blot electrophoretic cell
system (Bio-Rad). The membrane was blocked by incubation with
5% skim milk in TBS for 1 h at room temperature. Mouse sera, di-
luted 1:100 in TTBS (TBS with 0.05% tween 20, and 1% skim milk)
were added and incubated for 1 h at room temperature. The mem-
brane was then washed with TTBS three times. Goat anti-mouse
IgG antibodies conjugated with horseradish peroxidase (Sigma)
were diluted 1:500 in TTBS (TBS with 0.05% tween 20, 1% skim
milk) and used as secondary antibodies (1 h of incubation at room
temperature). Again, the membranes were washed with TTBS three
times and treated for detection with the CN/DAB substrate kit
(Pierce). A rabbit hyperimmune antiserum was raised against
P48, as previously described (Alberti et al., 2006), and used to de-
tect expression of rP48 in transfected HEK 293 cells. Western blots
were performed as described above and using peroxidase conju-
gate Protein G (Pierce) as a secondary antibody.
2.6. Assay for splenocyte proliferation and cytokine mRNA
quantiﬁcation
Mononuclear cells from the spleen, harvested and prepared
from mice as previously described (Xiao et al., 2004), were plated
in 96-well ﬂat-bottom plates at 100 ll per well (2  105 cells per
well). Subsequently 100 ll per well of medium with or without re-
combinant P48 (15 lg/ml) were added and mixed. Concanavalin A
(5 lg/ml; Sigma) was used as a positive control.
Each splenocyte sample was plated in triplicate. In order to
evaluate the speciﬁcity of the assay mononuclear cells were also
incubated in two independent experiments with recombinant
Mycoplasma Capricolum subsp. capricolum P60 (Alberti et al.,
2007). The proliferative response was measured by Cell Titer 96
AQueus one solution cell proliferation assay, according to vendors
instruction (Promega). Plates were read at 490 nm. The stimulation
index (SI) was calculated as the ratio of average OD value of wells
Fig. 1. Transcription of P48 gene (A) and P48 protein expression (B) as detected by
RT-PCR and immunoblotting in transfected HEK 293 cells. Cells were transfected
with different P48 expression plasmids (and with the relative negative controls) as
described in materials and methods. Total RNA was puriﬁed from transfected cells
and ampliﬁed by RT-PCR with P48-speciﬁc primers. Production of speciﬁc mRNA
(A) was assessed 48 h later in cells transfected with all the three plasmid tested. P48
protein was detected by immunoblotting (B) using a rabbit hyperimmune antise-
rum raised against P48 only in cells transfected with pVAX1/P48. Recombinant P48
was used as a positive control for immunoblotting. PL- Invitrogen BenchMarkTM Pre-
stained Protein Ladder (only the 40 kDa and 50 kDa bands are shown). PL: protein
ladder.
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ing only cells with medium. Complementary DNA was obtained
from total RNA extracted from mice spleen with Trizol reagent
(Invitrogen), by using the SuperScriptTM First-Strand Synthesis Sys-
tem (Invitrogen). Pairs of oligonucleotide primers effective on
mouse cytokines and Th transcription factors were chosen formFig. 2. Evaluation of humoral responses in mice vaccinated with pVAX1/P48 by immuno
mice (PS) collected at T3 speciﬁcally reacted with rP48, whereas pooled sera taken from
hyperimmune antiserum, used as a positive control. rP48-ELISA was used to evaluate IgG
mice. A signiﬁcant increase of total IgG (P = 0.03) and IgG1 (P = 0.03) could be detected by
not statistically signiﬁcant. Boxplots and P values were obtained by using the Anova anthe literature as follows: IFN-c and IL-2 (Ramos-Payan et al.,
2003); IL-12p40 and IL-4, (Liu et al., 2005); T-bet (Liu et al.,
2003); gata3 (Ise et al., 2002). Traditional PCR was used to evaluate
the selected oligonucleotides and establish the presence of differ-
ent cytokines expression levels in vaccinated and control mice.
The same primers were used in real time PCR experiments con-
ducted to investigate the relative quantities of each cytokine/tran-
scription factor in control and vaccinated groups. On the basis of
traditional RT-PCR results, primers previously selected for IFN-c
were discarded in favour of new generated oligonucleotides (IFN-
c/MOUSE/F: 50TACTGCCACGGCACAGTCAT 30, IFN-c/MOUSE/R: 50
tccttttgccagttcctcca 30). b-actin primers (Ramos-Payan et al.,
2003) were used in traditional and real time PCR to amplify b-actin,
selected as an internal control to normalize gene expression.
Real time PCR (7900HT Fast Real-Time PCR System, Applied Bio-
technologies) ampliﬁcations were performed by using the Plati-
num SYBR Green qPCR Super Mix – UDG following vendor
instructions (Invitrogen). Following an initial denaturation step of
2 min at 95 C, forty cycles of PCR were performed with cycling
conditions of 15 s at 95 C, and 60 s at 60 C. PCR signals were with
the relative quantiﬁcation DDCT option of the SDS 2.2.2 software,
by using D-Actin mRNA as an internal control to normalize the lev-
els of cytokine-speciﬁc mRNAs detected in different samples. Each
experiment was repeated at least three times.2.7. Antigen-speciﬁc ELISA analysis
The antibodies speciﬁc to P48 were analyzed. Brieﬂy, micro-
plates (Nunc maxysorp) were coated overnight uncovered at
37 C with 100 ng/well of rP48. After four washes, plates were
blocked with 150 ll/well of PBS containing 2.5% casein (Sigma),
incubated at 37 C for 1 h, and washed as before. Serum samples,
diluted 1:20 in PBS containing 1.25% casein, were incubated at
37 C for 2 h (100 ll/well).
Wells were then washed and incubated with 100 ng/ml perox-
idase (HRP) labeled goat anti-mouse IgG (Sigma), goat anti-mouseblotting (A) and rP48-ELISA (B, C). In the immunoblots (A), pooled sera of vaccinated
control mice () were always negative. PC = reactivity of rP48 against rP48 rabbit
(B), IgG1 (dark gray boxes in C), and IgG2a (white boxes in C) levels in vaccinated
rP48-ELISA only in vaccinated mice. An increase of IgG2a was also observed but was
d Mann-Whitney tests, respectively. PL = protein ladder.
Fig. 3. Proliferation of mononuclear cells in the spleen of mice injected with either
pVAX1 or pVAX1/P48 after stimulation with P48. The mean stimulation index (SI) of
vaccinated mice (injected with pVAX1/P48) was nearly 5 times greater then mean
SI of control mice (Injected with pVAX1 only). Boxplots and P values were obtained
by using the Anova and Mann–Whitney tests, respectively.
Fig. 4. Relative quantity (RQ) of cytokines expressed in spleen of mice injected with pVA
of transcription factors T-bet and GATA-3 are also given. Vaccinated mice produce signiﬁc
Th1 cytokines, such as IFN-c, IL-12, IL-2 were predominantly expressed.
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Cruz). After ﬁnal washes, the enzymatic reaction was developed
with p-nitrophenyl phosphate in 3,30,5,50-tetramethylbenzidine
solution (Zymed Labs), stopped after 5 min by adding 0.2 M sul-
phuric acid and read at 450 nm. Box plots of ELISA absorbances
were obtained for mice belonging to control and vaccinated groups
at each sampling time by Minitab.
2.8. Statistical evaluation
The signiﬁcance of differences of medians and means between
the two groups was evaluated with Minitab (Minitab release
13.0), by using the non parametric Mann-Whitney and the Anova
tests, respectively. All conclusions were based on signiﬁcance lev-
els of P < 0.05. Boxplots representative of results were generated by
using the same software.X1 (control), or pVAX1/P48, as evaluated by reverse transcription real-time PCR. RQ
antly higher levels of cytokines respect to mice injected only with the vector pVAX1.
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3.1. Construction and expression of plasmid carrying P48 gene
Nucleic acid immunization has been reported to induce both
humoral and cellular immunity in many infectious disease models
(Lowe et al., 2006). Plasmids pcDNA3.1/P48, pVAX1/P48, and
pCMV-Script/P48 were constructed in order to investigate the po-
tential of a plasmid carrying the 48 kDa antigen gene of M. agalac-
tiae in eliciting immune responses. To ensure that P48 could
indeed be transcribed in mammalian cells, the presence of speciﬁc
mRNA was established by RT-PCR from total RNA isolated from
HEK 293 cells transfected with the three plasmids. As shown in
Fig. 1, an amplicon of approximately 1.3 kb was obtained both
from cells transfected independently with the three plasmids,
and from plasmid pGEX-2T/P48 used as a positive control for PCR
(Fig. 1A). However, as we attempted to detect P48 in HEK 293 cell
lysates by immunoblotting, we were able to clearly observe the ex-
pected protein only in immunoblots of cells transfected with
pVAX1/P48 (Fig. 1B). DNA sequencing conﬁrmed the correct clon-
ing of p48 in pVAX1. pVAX1/P48 was therefore chosen for nucleic
acid immunizations.
3.2. Evaluation of humoral immune responses by pVAX1/P48
vaccination
The humoral immune responses induced by pVAX1/P48 vacci-
nation were analyzed in mice by immunoblotting and rP48-ELISA.
As shown in Fig. 2A, P48-speciﬁc IgG antibodies were only detected
in pooled sera taken from vaccinated mice at Tf. Pooled sera of mice
taken from the control group at the same sampling time never re-
acted with rP48. We tentatively used ELISA to clarify the IgG sub-
class and quantify antibodies (Fig. 2B–C). No statistically
signiﬁcant difference of IgG titers was detected between sera taken
at T0, T1, T2, T3 from control mice, whereas IgG titers of vaccinated
mice at Tf were signiﬁcantly different from titers of sera taken from
the same mice at T0. However, when sera of vaccinated mice taken
at different sampling times were tested for the presence of differ-
ent antibodies subclasses, we failed to detect a statistically signif-
icant increase of IgG2a levels while still detecting a statistically
signiﬁcant increase of IgG1 levels. It should be noted that, a pro-
gressive increase of the IgG2a absorbances medians in vaccinated
mice (even if not statistically supported) was observed.
3.3. Proliferation of mononuclear cells in the spleen
To determine whether P48-speciﬁc proliferation responses
were induced in the immunized animals, the proliferation of
mononuclear cells in the spleen was measured. Mononuclear cells
from the spleens were harvested from mice eight weeks after the
ﬁrst inoculation with pVAX1/P48 (or with pVAX1, alternatively),
and were stimulated with puriﬁed P48 protein for 72 h. As shown
in Fig. 3, P48-speciﬁc proliferation in mononuclear cells of the
spleen was efﬁciently induced by pVAX1/P48 vaccination. The
mean stimulation index was estimated to be 4.8 in mice injected
with pVAX1/P48. By contrast, no proliferation of mononuclear cells
was found in pVAX1-immunized mice. Proliferation was never ob-
served in experiments where Mycoplasma Capricolum subsp. capri-
colum P60 was used to stimulate mononuclear cells of the spleen
(data not shown).3.4. Cytokine-speciﬁc mRNA in mononuclear cells
To assay cytokine-speciﬁc mRNAs released from mononuclear
spleen cells 8 weeks after the ﬁrst immunization with pVAX1/P48, cytokine mRNAs were analyzed by reverse transcription real
time PCR. As shown in Fig. 4, spleen cells of mice injected with
pVAX1/P48 synthesized amounts of IFN-c, IL-12, IL-2 mRNAs sig-
niﬁcantly higher than the same cells taken frommice injected with
the vector pVAX1 only. A slight increase of T-bet, IL-4, and GATA-3
was also observed in mice immunized with pVAX1/P48.4. Discussion and conclusions
The control ofM. agalactiae through vaccination is an increasing
challenge. Although several inactivated vaccines have provided
protection to Ca (Tola et al., 1999; Greco et al., 2002; Nicholas,
2002), they carry intrinsic disadvantages (e.g. DIVA diagnostics
hampering, selection and use of adjuvants, requirements for multi-
ple injections), and only produce a short-lived humoral immune
response. Vaccination with plasmid DNA is an active area of inves-
tigation that is being applied to cancer and microbial pathogens
associated with infectious diseases (Lowe et al., 2006). DNA vac-
cines have been reported to persist in muscle for over one year,
they induce effective immune responses with bacterial antigens,
and are simply produced (Wolff et al., 1992; Gurunathan et al.,
2000). Recent investigations suggested that the genetic vaccination
approach may induce both humoral and cellular immunities and
represent a potentially new approach to design vaccines against
mycoplasmas (Barry et al., 1995; Chen et al., 2003; Lai et al.,
1997; March et al., 2006).
In this study, a pVAX1-based plasmid expressing the P48 of M.
agalactiae was designed and evaluated. As shown in Fig. 1, P48
mRNA was observed in transfected HEK 293 cells, and the P48 pro-
tein level was high enough to be detected by Western blotting. The
production of P48-speciﬁc antibodies and the proliferation of
spleen cells in pVAX1/P48-immunized mice (Figs. 2 and 3) further
conﬁrmed that P48 was expressed and induced signiﬁcant immune
responses in the immunized animals.
CpGmotif acts as a ‘‘danger signal” and as a Th1 immune response
enhancer in DNA vaccination through interaction with TLR9-posi-
tive cells (Liu et al., 2005). In addition to the CpG motifs contained
in pVAX1, pVAX1/P48 contains two CpGmotifs, ggCGtt and aaCGct,
located in the p48 gene sequence, while hexameric CpG motifs
which may inhibit the immunogenicity of DNA vaccines (Krieg
et al., 1998; Stratford et al., 2001) are absent in the same region.
P48 is an immunodominat invariable lipoprotein exposed on
the membrane of M. agalactiae and belongs to the basic membrane
protein family. The p48 gene (Rosati et al., 1999) and its homo-
logues in Mycoplasma bovis (Robino et al., 2005), M. capricolum
subsp. capricolum (Alberti et al., 2007), and Mycoplasma mycoides
subsp. mycoides LC (unpublished data) are located upstream the
ATP binding protein of an ABC transporter. P48 shares signiﬁcant
homology with several solute binding proteins of ABC transporters
found in mycoplasmas and in other bacterial species. Indeed, P48
shares strong levels of homology with the ABC transporter Xylose
binding protein of Mycoplasma pulmonis (E value 8e-30), Myco-
plasma hypneumoniae (E value 1e-27), and Mycoplasma synoviae
(E value 3e-22), and with solute binding proteins of uncharacter-
ized ABC-type transport systems of Oenococcus oeni (E value 5e-
08), Clostridium sticklandii (E value 5e-07), and Spiroplasma citri
(E value 9e-08). These data indicate a putative function as solute
binding protein also for P48 of Mycoplasma agalactiae. It has been
shown that ABC transporters are highly immunogenic and repre-
sent ideal targets for the development of antibacterial vaccines.
(Garmory and Titball, 2004). As an example, immunization with
the iron uptake ABC transporter proteins PiaA and PiuA prevents
respiratory and systemic infection with Streptococcus pneumoniae
(Brown et al., 2001; Jomaa et al.,2006). Therefore P48, as a putative
solute binding protein, may confer additional immunostimulatory
B. Chessa et al. / Research in Veterinary Science 86 (2009) 414–420 419effects and may represent an ideal candidate for the development
of a DNA vaccine against M. agalactiae.
DNA vaccination has been demonstrated to induce both humor-
al and cellular immune responses. Th1 cells can activate macro-
phages to destroy intracellular microorganisms more efﬁciently
and also activate B cells to produce strongly opsonizing antibodies
such as IgG2a and IgG2b in mice (Gurunathan et al., 2000). The
main effector function of Th2 cells is to drive B cells to proliferate
and produce antibodies such as IgG1 and other types. A signiﬁcant
but weak increase of IgG in mice vaccinated with pVAX1/P48 was
observed, apparently associated to the IgG1 subclass. We failed to
observe an increase of IgG2a by rP48-ELISA. It was shown (Laylor
et al., 1999) that priming and boosting of mice with the DNA vector
pEE6DS-hCGß, expressing sequences encoding a transmembrane
version of the b-chain of human chorionic gonadotropin (hCGb),
was not followed by detection of appreciable levels of speciﬁc anti-
body. However, subsequent challenge with hCG protein in Ribi
adjuvant elicited a strong and rapid secondary immune response.
This response was of comparable magnitude to that produced fol-
lowing priming, boosting and challenge with protein in adjuvant.
Therefore, DNA vaccination favours memory rather then effector
B cell responses. According to this, and to the levels of antibodies
detected in vaccinated mice, pVAX1/P48 may have efﬁciently
primed the humoral immune response.
Proliferation of CD4+ cells and cytokines expression proﬁles in
the spleen, are typical of a Th1 immune response. Indeed high lev-
els of IFN-c, IL-12, and IL-2 were detected in spleens of immunized
mice. A slight increase of IL-4 was also observed in the same sam-
ples. The two transcription factors T-bet and GATA-3, associated to
Th1 and Th2 modulation, respectively, were both weakly activated
in mice immunized with pVAX1/P48.
In conclusion we present evidence that DNA vaccination with
pVAX1/P48 may induce speciﬁc Th1 and Th2 responses and repre-
sent a potentially new approach to design vaccines against M. aga-
lactiae. We can not obviously make general predictions based on
the immune responses of mice, and the potential of using
pVAX1/P48 immunization for the control of contagious agalactia
will be evaluated in sheep. The immunization (and challenge) of
sheep will take into account the enhancement of humoral immu-
nity through the prime-boost strategy (Dale et al., 2006), that is,
priming with pVAX1/P48 and boosting with rP48.Acknowledgments
This work was supported by Italian MIUR grant PRIN 2003 prot.
2003071315 and from the ‘‘Regione Autonoma della Sardegna”
Grant Ricerca sanitaria ﬁnalizzata 2006, UPB S 12 025 cap. 12012.References
Alberti, A., Addis, M.F., Chessa, B., Cubeddu, T., Proﬁti, M., Rosati, S., Ruiu, A., Pittau,
M., 2006. Molecular and antigenic characterization of aMycoplasma bovis strain
causing an outbreak of infectious keratoconjunctivitis. J. Vet. Diagn. Invest. 18,
41–51.
Alberti, A., Robino, P., Chessa, B., Rosati, S., Addis, M.F., Mercier, P., Mannelli, A.,
Cubeddu, T., Proﬁti, M., Bandino, E., Thiery, R., Pittau, M., 2007. Characterisation
of Mycoplasma capricolum P60 surface lipoprotein and its evaluation in a
recombinant ELISA. Vet. Microbiol.. doi:10.1016/j.vetmic.2007.09.020.
Barry, M.A., Lai, W.C., Johnston, S.A., 1995. Protection against mycoplasma infection
with expression-library immunization. Nature 377, 632–635.
Bergonier, D., Bertholet, X., Poumarat, F., 1997. Contagious agalactia of small
ruminants: current knowledge concerning epidemiology, diagnosis and control.
Rev. Sci. Tech. Off. Int. Epizoot. 16, 848–873.
Brandsma, J.L., 2006. DNA vaccine design. Methods Mol. Med. 127, 3–10.
Brown, J.S., Ogunniyi, A.D., Woodrow, M.C., Holden, D.W., Paton, J.C., 2001.
Immunization with components of two iron uptake ABC transporters protects
mice against systemic Streptococcus pneumoniae infection. Infect. Immun. 69,
6702–6706.Chen, Y.L., Wang, S.N., Yang, W.J., Chen, Y.J., Lin, H.H., Shiuan, D., 2003. Expression
and immunogenicity of Mycoplasma hyopneumoniae heat shock protein antigen
P42 by DNA vaccination. Infect. Immun. 71, 1155–1160.
Citti, C., Watson-McKown, R., Droesse, M., Wise, K.S., 2000. Gene families encoding
phase- and size-variable surface lipoproteins of Mycoplasma hyorhinis. J.
Bacteriol. 182, 1356–1363.
Cottew, G.S., 1979. Caprine-ovine mycoplasmas. In: Tully, J.G., Whitcomb, R.F.
(Eds.), The Mycoplasmas, vol. II. Academic Press, New York, pp. 103–132.
Da Massa, A.J., 1983. Recovery of Mycoplasma agalactiae from mastitic goat milk. J.
Am. Vet. Med. Assoc. 183, 548–554.
Dale, C.J., Thomson, S., De Rose, R., Ranasinghe, C., Medveczky, C.J., Pamungkas, J.,
Boyle, D.B., Ramshaw, I.A., Kent, S.J., 2006. Prime-boost strategies in DNA
vaccines. Methods Mol. Med. 127, 171–197.
Davis, K.L., Wise, K.S., 2002. Site-speciﬁc proteolysis of the MALP-404 lipoprotein
determines the release of a soluble selective lipoprotein-associated motif-
containing fragment and alteration of the surface phenotype of Mycoplasma
fermentans. Infect. Immun. 70, 1129–1135.
Garmory, H.S., Titball, R.W., 2004. ATP-binding cassette transporters are targets for
the development of antibacterial vaccines and therapies. Infect. Immun. 69,
6702.
Gil, M.C., Hermosa De Mendoza, M., Rey, J., Alonso, J.M., Poveda, J.B., Hermosa De
Mendoza, J., 1999. Aetiology of caprine contagious agalactia syndrome in
Extremudura. Spain Vet. Rec. 144, 24–25.
Glew, M.D., Papazisi, L., Poumarat, F., Bergonier, D., Rosengarten, R., Citti, C., 2000.
Characterization of a multigene family undergoing high-frequency DNA
rearrangements and coding for abundant variable surface proteins in
Mycoplasma agalactiae. Infect. Immun. 68, 4539–4548.
Greco, G., Corrente, M., Buonavoglia, D., Aliberti, A., Fasanella, A., 2002. Inactivated
vaccine induces protection against Mycoplasma agalactiae infection in sheep.
New Microbiol. 25, 17–20.
Gurunathan, S., Klinman, D.M., Seder, R.A., 2000. DNA vaccines: immunology,
Application, and optimization. Annu. Rev. Immunol. 18, 927–974.
Ise, W., Totsuka, M., Sogawa, Y., Ametani, A., Hachimura, S., Sato, T., Kumagai, Y.,
Habu, S., Kaminogawa, S., 2002. Naive CD4+ T cells exhibit distinct expression
patterns of cytokines and cell surface molecules on their primary responses to
varying doses of antigen. J. Immunol. 168, 3242–3250.
Jomaa, M., Terry, S., Hale, C., Jones, C., Dougan, G., Brown, J., 2006. Immunization
with the iron uptake ABC transporter proteins PiaA and PiuA prevents
respiratory infection with Streptococcus pneumoniae. Vaccine 24, 5133–
5139.
Krieg, A.M., Wu, T., Weeratna, R., Eﬂer, S.M., Love-Homan, L., Yang, L., Yi, A.K., Short,
D., Davis, H.L., 1998. Sequence motifs in adenoviral DNA block immune
activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. 95, 12631
–12636.
Laddy, D.J., Weiner, D.B., 2006. From plasmids to protection: a review of DNA
vaccines against infectious diseases. Int. Rev. Immunol. 25, 99–123.
Lai, W.C., Pakes, S.P., Ren, K., Lu, Y.S., Bennett, M., 1997. Therapeutic effect of DNA
immunization of genetically susceptible mice infected with virulent
Mycoplasma pulmonis. J. Immunol. 158, 2513–2516.
Lambert, M., 1987. Contagious agalactia of sheep and goats. Rev. Sci. Tech. Off. Int.
Epizoot. 6, 699–711.
Laylor, R., Porakishvili, N., De Souza, J.B., Playfair, J.H., Delves, P.J., Lund, T., 1999.
DNA vaccination favours memory rather than effector B cell responses. Clin.
Exp. Immunol. 117, 106–112.
Liu, L., Zhou, X., Liu, H., Xiang, L., Yuan, Z., 2005. CpG motif acts as a ‘danger signal’
and provides a T helper type 1-biased microenvironment for DNA vaccination.
Immunology 115, 223–230.
Liu, N., Ohnishi, N., Ni, L., Akira, S., Bacon, K.B., 2003. CpG directly induces T-bet
expression and inhibits IgG1 and IgE switching in B cells. Nat. Immunol. 4, 687–
693.
Lowe, D.B., Shearer, M.H., Kennedy, R.C., 2006. DNA vaccines: successes and
limitations in cancer and infectious disease. J. Cell. Biochem. 98, 235–242.
March, J.B., Jepson, C.D., Clark, J.R., Totsika, M., Calcutt, M.J., 2006. Phage library
screening for the rapid identiﬁcation and in vivo testing of candidate genes for a
DNA vaccine against Mycoplasma mycoides subsp. Mycoides small colony
biotype. Infect. Immun. 74, 167–174.
Nicholas, R.A.J., 2002. Improvements in the diagnosis and control of diseases of
small ruminants caused by mycoplasmas. Small Ruminant Res. 45, 145–149.
Nicholas, R.A.J., 2005. Contagious agalactia and other mycoplasmal mastitides of
small ruminants. In: Kahn, C.M., Line, S. (Eds.), The Merck Veterinary Manual,
9th ed. Merck & Co. Inc., Whitehouse Station, NJ, pp. 1114–1116.
Ramos-Payan, R., Aguilar-Medina, M., Estrada-Parra, S., Gonzalez, Y.M.J., Favila-
Castillo, L., Monroy-Ostria, A., Estrada-Garcia, I.C., 2003. Quantiﬁcation of
cytokine gene expression using an economical realtime polymerase chain
reaction method based on SYBR Green I. Scand. J. Immunol. 57, 439–445.
Razin, S., Yogev, D., Naot, Y., 1998. Molecular biology and pathogenicity of
mycoplasmas. Microbiol. Mol. Biol. Rev. 62, 1094–1156.
Robino, P., Alberti, A., Pittau, M., Chessa, B., Miciletta, M., Nebbia, P., Le Grand, D.,
Rosati, S., 2005. Genetic and antigenic characterization of the surface
lipoprotein P48 of Mycoplasma bovis. Vet. Microbiol. 109, 201–209.
Rosati, S., Robino, P., Fadda, M., Pozzi, S., Mannelli, A., Pittau, M., 2000. Expression
and antigenic characterization of recombinantMycoplasma agalactiae P48 major
surface protein. Vet. Microbiol. 71, 201–210.
Rosati, S., Pozzi, S., Robino, P., Montinaro, B., Conti, A., Fadda, M., Pittau, M., 1999.
P48 major surface antigen of Mycoplasma agalactiae is homologous to a malp
420 B. Chessa et al. / Research in Veterinary Science 86 (2009) 414–420product of Mycoplasma fermentans and belongs to a selected family of bacterial
lipoproteins. Infect. Immun. 67, 6213–6216.
Santona, A., Carta, F., Fraghi, P., Turrini, F., 2002. Mapping antigenic sites of an
immunodominant surface lipoprotein of Mycoplasma agalactiae, AvgC, with the
use of synthetic peptides. Infect. Immun. 70, 171–176.
Stratford, R., Gouce, G., Zhang-Barber, L., Faairweather, N., Eskola, J., Dougan, G.,
2001. Inﬂuence of codon usage on the immunogenicity of a DNA vaccine against
tetanus. Vaccine 19, 810–815.
Tola, S., Manunta, D., Rocca, S., Rocchiagiani, A.M., Idini, G., Angioi, P.P., Leori, G.,
1999. Experimental vaccination against Mycoplasma agalactiae using different
inactivated vaccines. Vaccine 10, 2764–2768.van Oirschot, J.T., 2001. Present and future of veterinary viral vaccinology: a review.
Vet. Q. 23, 100–108.
Wolff, J.A., Ludtke, J.J., Acsadi, G., Williams, P., Jani, A., 1992. Long term persistence
of plasmid DNA and foreign gene expression in muscle. Hum. Mol. Genet. 1,
363–369.
Xiao, S., Chen, H., Fang, L., Liu, C., Zhang, H., Jiang, Y., Hong, W., 2004. Comparison of
immune responses and protective efﬁcacy of suicidal DNA vaccine and
conventional DNA vaccine encoding glycoprotein C of pseudorabies virus in
mice. Vaccine 22, 345–351.
Zhang, Q., Young, T.F., Ross, R.F., 1995. Identiﬁcation and characterization of a
Mycoplasma hyopneumoniae adhesin. Infect. Immun. 63, 1013–1019.
